Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang; Suresh Senan; Marinus A. Paul; Reza J. Mehran; Alexander V. Louie; Peter Balter; Harry J. M. Groen; Stephen E. McRae; Joachim Widder; Lei Feng; Ben E. E. M. van den Borne; Mark F. Munsell; Coen Hurkmans; Donald A. Berry; Erik van Werkhoven; John J. Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J. A. Haasbeek; Larry S. Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J. Slotman; Egbert F. Smit; Jack A. Roth

doi:10.1016/S1470-2045(15)70168-3

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang^*, Suresh Senan, Marinus A. Paul, Reza J. Mehran, Alexander V. Louie, Peter Balter, Harry J. M. Groen, Stephen E. McRae, Joachim Widder, Lei Feng, Ben E. E. M. van den Borne, Mark F. Munsell, Coen Hurkmans, Donald A. Berry, Erik van Werkhoven, John J. Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelis J. A. Haasbeek, Larry S. CarpenterKatrien De Jaeger, Ritsuko Komaki, Ben J. Slotman, Egbert F. Smit, Jack A. Roth

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (

Original language	English
Pages (from-to)	630-637
Journal	Lancet oncology
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/S1470-2045(15)70168-3
Publication status	Published - Jun 2015

Access to Document

10.1016/S1470-2045(15)70168-3

Cite this

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., van den Borne, B. E. E. M., Munsell, M. F., Hurkmans, C., Berry, D. A., van Werkhoven, E., Kresl, J. J., Dingemans, A.-M., Dawood, O., Haasbeek, C. J. A., ... Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet oncology, 16(6), 630-637. https://doi.org/10.1016/S1470-2045(15)70168-3

@article{f52fac16f62442d5874a92499b82f616,

title = "Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials",

abstract = "Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (",

author = "Chang, {Joe Y.} and Suresh Senan and Paul, {Marinus A.} and Mehran, {Reza J.} and Louie, {Alexander V.} and Peter Balter and Groen, {Harry J. M.} and McRae, {Stephen E.} and Joachim Widder and Lei Feng and {van den Borne}, {Ben E. E. M.} and Munsell, {Mark F.} and Coen Hurkmans and Berry, {Donald A.} and {van Werkhoven}, Erik and Kresl, {John J.} and Anne-Marie Dingemans and Omar Dawood and Haasbeek, {Cornelis J. A.} and Carpenter, {Larry S.} and {De Jaeger}, Katrien and Ritsuko Komaki and Slotman, {Ben J.} and Smit, {Egbert F.} and Roth, {Jack A.}",

year = "2015",

month = jun,

doi = "10.1016/S1470-2045(15)70168-3",

language = "English",

volume = "16",

pages = "630--637",

journal = "Lancet oncology",

issn = "1470-2045",

publisher = "The Lancet Publishing Group",

number = "6",

}

Chang, JY, Senan, S, Paul, MA, Mehran, RJ, Louie, AV, Balter, P, Groen, HJM, McRae, SE, Widder, J, Feng, L, van den Borne, BEEM, Munsell, MF, Hurkmans, C, Berry, DA, van Werkhoven, E, Kresl, JJ, Dingemans, A-M, Dawood, O, Haasbeek, CJA, Carpenter, LS, De Jaeger, K, Komaki, R, Slotman, BJ, Smit, EF & Roth, JA 2015, 'Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials', Lancet oncology, vol. 16, no. 6, pp. 630-637. https://doi.org/10.1016/S1470-2045(15)70168-3

TY - JOUR

T1 - Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

AU - Chang, Joe Y.

AU - Senan, Suresh

AU - Paul, Marinus A.

AU - Mehran, Reza J.

AU - Louie, Alexander V.

AU - Balter, Peter

AU - Groen, Harry J. M.

AU - McRae, Stephen E.

AU - Widder, Joachim

AU - Feng, Lei

AU - van den Borne, Ben E. E. M.

AU - Munsell, Mark F.

AU - Hurkmans, Coen

AU - Berry, Donald A.

AU - van Werkhoven, Erik

AU - Kresl, John J.

AU - Dingemans, Anne-Marie

AU - Dawood, Omar

AU - Haasbeek, Cornelis J. A.

AU - Carpenter, Larry S.

AU - De Jaeger, Katrien

AU - Komaki, Ritsuko

AU - Slotman, Ben J.

AU - Smit, Egbert F.

AU - Roth, Jack A.

PY - 2015/6

Y1 - 2015/6

N2 - Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (

AB - Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (

U2 - 10.1016/S1470-2045(15)70168-3

DO - 10.1016/S1470-2045(15)70168-3

M3 - Article

SN - 1470-2045

VL - 16

SP - 630

EP - 637

JO - Lancet oncology

JF - Lancet oncology

IS - 6

ER -